ClinicalTrials.gg
RecruitingNCT06428682Updated Jun 5, 2024

Role of TXA in Patients Undergoing Breast Free Flap Reconstruction

A Phase 4 interventional study of Tranexamic acid and Placebo in Breast Cancer and Blood Loss, Surgical, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-05.

Sponsored by University of Virginia · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Breast Neoplasms by University of Virginia — 6 open to participants now, 7 under way, 2 of them phase 3. Breast Neoplasms · University of Virginia.

Planned enrollment
6th of 17
100 · median 45
Started
2024
with 1 other
Phase 4
Only one
of the 18
Registered
13th of 18
by date

Among the 18 studies in Breast Neoplasms by University of Virginia, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 4, and was the 13th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 18 studies in Breast Neoplasms by University of Virginia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Breast Neoplasms by University of Virginia, or all of them as a file.
02

Study summary

Tranexamic acid (TXA) is a synthetic, competitive lysine receptor inhibitor on plasminogen. It ultimately stabilizes the fibrin matrix, therefore used as a hemostatic agent for various indications. While there has been indications for orthopedic and trauma surgery, there is no clear data for its role in patients who are undergoing free tissue transfer. Studies have shown that patients undergoing free tissue transfer can have transfusion rates ranging from 7.2% to 34.9%, which data also showing association between transfusion requirement and higher free flap failure rate. There has been a few retrospective studies that evaluated the effect of TXA in free tissue transfer and the results showed no increased risk of microanastomosis failure but some showing decreased blood loss. This study aims to further analyze the role of TXA in patients undergoing breast free flap reconstruction with randomized, prospective trial. Control group will not receive TXA while experimental group will receive TXA. Both groups will receive standard of care breast free flap surgery as well as post-op care, which is streamlined with Early Recovery After Surgery (ERAS) protocol. Their pre and post-op hemoglobin will be compared, as well as rates of transfusion, surgical outcome and surgical complications including hematoma, flap failure, and any other medical complications such as Deep Vein Thrombosis (DVT)/ Pulmonary Embolism (PE).

03

Conditions studied

  • Breast Cancer
  • Blood Loss, Surgical

Keywords

  • Autologous breast reconstruction
  • Free Flap
  • Tranexamic Acid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All female patients who are 18 years or older who will undergo unilateral or bilateral abdomen-based free flap breast reconstruction at UVA Medical Center

Exclusion criteria

Exclusion Criteria:

  • Subjects with ages \<18 years
  • Allergy to TXA
  • Subjects who has to TXA: anyone who has active intravascular thrombosis or anyone with subarachnoid hemorrhage
  • Subjects who have anemia (defined as baseline \<8 g/dL
  • Subjects who cannot read or understand English
  • Subjects who are pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    TXA group

    Women undergoing immediate or delayed free flap breast reconstruction and receiving IV TXA

    Drug: Tranexamic acid

  • Placebo comparator
    Placebo group

    Women undergoing immediate or delayed free flap breast reconstruction and receiving same volume of IV saline

    Drug: Placebo

Interventions

  • Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.

  • DrugPlacebo

    Control group will receive same volume equivalent of saline intravenously at the time of their surgery.

06

What researchers measure

Primary outcomes

  1. Delta Hemoglobin

    Post-op day 1 Hemoglobin - Pre-op Hemoglobin

    Time frame: 1 day after surgery

  2. Transfusion rate

    Transfusion rate during hospital stay

    Time frame: Typically 0-72 hours after surgery

Secondary outcomes

  1. Surgical complications

    Thromboembolic event, hematoma, seroma, flap compromise/ failure

    Time frame: 30 days after surgery

  2. Length of Stay

    Total length of stay after surgery

    Time frame: typically 2-4 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2025, 12 months after the start.

Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 12 months is below that.

Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2024
First posted
May 24, 2024
StartActual
May 13, 2024
Primary completionEst.
May 13, 2025
CompletionEst.
May 13, 2026
Last update
Jun 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06428682
Responsible party
John Stranix (Assistant Professor of Plastics Surgery, University of Virginia) — Principal investigator
First posted
May 24, 2024
Start date
May 13, 2024
Primary completion
May 13, 2025 (estimated)
Completion
May 13, 2026 (estimated)
Last update
Jun 5, 2024

Study contacts

Rachel Park, MD
Contact
RHP7GU@uvahealth.org
5714287278
John Stranix, MD
principal investigator · University of Virginia

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion